You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • Type of vaccine and immunosuppressive therapy but not diagnosis critically influence antibody response after COVID-19 vaccination in patients with rheumatic disease

Article info

Article menu

Download PDFPDF

Epidemiology
Original research
Type of vaccine and immunosuppressive therapy but not diagnosis critically influence antibody response after COVID-19 vaccination in patients with rheumatic disease

Authors

  • Leonie Maria Frommert Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Amanthi Nadira Arumahandi de Silva Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Jan Zernicke Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Veronika Scholz Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Tanja Braun Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Lara Maria Jeworowski Institute of Virology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, GermanyGerman Centre for Infection Research (DZIF), Associated Partner Site, Berlin, Germany PubMed articlesGoogle scholar articles
  • Tatjana Schwarz Institute of Virology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, GermanyGerman Centre for Infection Research (DZIF), Associated Partner Site, Berlin, Germany PubMed articlesGoogle scholar articles
  • Pinkus Tober-Lau Department of Infectious Diseases and Respiratory Medicine, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Alexander ten Hagen Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Elisa Habermann Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Florian Kurth Department of Infectious Diseases and Respiratory Medicine, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Leif Erik Sander Department of Infectious Diseases and Respiratory Medicine, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Victor Max Corman Institute of Virology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, GermanyGerman Centre for Infection Research (DZIF), Associated Partner Site, Berlin, GermanyLabor Berlin, Charité - Vivantes GmbH, Berlin, Germany PubMed articlesGoogle scholar articles
  • Gerd-Rüdiger Burmester Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Robert Biesen Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Fredrik N. Albach Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany PubMed articlesGoogle scholar articles
  • Jens Klotsche Epidemiology Unit, German Rheumatism Research Center Berlin – a Leibniz Institute (DRFZ), Berlin, Germany PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Fredrik N. Albach; fredrik.albach{at}charite.de
View Full Text

Citation

Frommert LM, Arumahandi de Silva AN, Zernicke J, et al
Type of vaccine and immunosuppressive therapy but not diagnosis critically influence antibody response after COVID-19 vaccination in patients with rheumatic disease
RMD Open 2022;8:e002650. doi: 10.1136/rmdopen-2022-002650

Publication history

  • Received August 8, 2022
  • Accepted November 1, 2022
  • First published December 6, 2022.
Online issue publication 
June 27, 2023

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.